Results 171 to 180 of about 121,038 (379)
ARID1B, a molecular suppressor of erythropoiesis, is essential for the prevention of Monge’s disease [PDF]
, 2022 Priti Azad +12 more
openalex +1 more source
When, which and how to switch: Navigating JAK inhibitors in myelofibrosis
British Journal of Haematology, EarlyView.Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan +2 more
wiley +1 more source
HSCB, a co-chaperone in mitochondrial iron-sulfur cluster biogenesis, is a novel candidate gene for congenital sideroblastic anemia [PDF]
, 2017 Congenital sideroblastic anemias (CSA) are inherited diseases resulting from defects in heme biosynthesis, mitochondrial iron-sulfur cluster (ISC) assembly, or mitochondrial translation.
Crispin, Andrew
core
British Journal of Haematology, EarlyView.In this post hoc analysis of the phase 2 BEYOND trial, the majority of patients with non‐transfusion‐dependent β‐thalassaemia achieved clinically meaningful haemoglobin levels ≥10.0 g/dL and increases from baseline ≥1.0 g/dL, thresholds associated with reduced risk of morbidity and mortality and recommended as an indication and target for treatment by ...
Khaled M. Musallam +11 more
wiley +1 more source
Modulation of in vitro erythropoiesis. The influence of beta-adrenergic agonists on erythroid colony formation. [PDF]
, 1977 James E. Brown, J W Adamson
openalex +1 more source
Grab and go: transferrin uptake in erythropoiesis [PDF]
, 2022 An‐Sheng Zhang, Caroline Enns
openalex +1 more source
Cell Proliferation, EarlyView.Decreased sialic acid increases the adhesion of RBC membranes to immunoglobulins leading to an increased erythrocyte sedimentation rate (ESR). The increase in reactive oxygen species (ROS) damages the sialic acid glycosyl chains on the surface of RBC membrane proteins, causing the membrane proteins to be overexposed to the plasma environment due to the
Sicheng Bian +16 more
wiley +1 more source
IL‐6 in the spotlight: From cardiovascular pathophysiology to therapy
European Journal of Clinical Investigation, EarlyView.Interleukin‐6 (IL‐6) links inflammation to cardiovascular and multi‐organ dysfunction. This review integrates mechanistic, translational, and clinical evidence supporting IL‐6 as both a biomarker and therapeutic target in the continuum of cardiovascular and cardio‐renal disease.
Alberto Preda +13 more
wiley +1 more source